Skilpadda AS
1
627K
1
1.00
- Stages of investment
- Areas of investment
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 1.00
- Investments by industry
- Information Technology (1)
- Internet (1)
- Insurance (1)
- Investments by region
- Norway (1)
- Peak activity year
- 2020
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 3
- Avg. valuation at time of investment
- 1M
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| LifePlanner | 01 Dec 2020 | Internet, Information Technology, Insurance | Seed | 627K | Vestland, Bergen, Norway |
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Proxima (formerly VantAI), a NYC-based AI-native biotech company developing AI-driven drug discovery for proximity therapeutics | Jan 13, 2026 | AI-driven drug discovery, Machine learning, Proteomics platform | - | 80000000 USD | a NYC-based AI-native biotech company |
| Relation | Dec 11, 2025 | AI, Biopharmaceutical, Bone Disease, Immunology, Metabolic Disease | - | 26000000 USD |  London, |
| Weave Bio | Oct 17, 2025 | AI-native regulatory automation management, Cloud-based software platform, Pharmaceutical companies, biotech firms, CROs, and regulatory consultants, Regulatory content preparation and lifecycle management | - | 20000000 USD |  San Francisco, California |
| Terrain Biosciences | Feb 14, 2025 | AI-guided sequence design tools, Machine-learning models for RNA sequence design, RNA-based therapies and vaccines, RNA design-build, RNA manufacturing, RNA therapeutics | - | 9000000 USD | Cambridge, Massachusetts |
| RiPSIM | Oct 29, 2024 | 4G/5G Private Network Operators, Cloud-native, eSIM-as-a-Service, Microservices, Software Platform, Wireless Service Providers | Early stage | 5000000 USD | Ashburn, Virginia |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.